DUBLIN, April 5, 2017 /PRNewswire/ --Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it is seeking to refinance its existing credit facilities with new senior secured credit facilities consisting of a revolving credit facility and a term loan facility (the "New Credit Facilities"). Endo intends to use the net proceeds of the New Credit Facilities, together with the net proceeds of other debt (which may be secured), to repay all outstanding loans and other obligations under its existing credit facilities and for general corporate purposes (collectively, the "Transactions"). The New Credit Facilities are expected to be guaranteed by Endo and certain of its subsidiaries. These Transactions, if completed, would not be expected to materially change Endo's total debt.
The Transactions are subject to market and other conditions and are anticipated to close in the second quarter of 2017. However, there can be no assurance that the Transactions will be consummated on the terms described herein or at all.
About Endo International plc
Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
Forward-Looking Statements
This press release contains "forward-looking statements" including, but not limited to, the statements relating to the Transactions, the expected timing of the closing of the Transactions and our ability to close such Transactions. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes, including regulatory decisions; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; the outcome of litigation, settlement discussions or other adverse proceedings; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo's periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval ("SEDAR"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.
This press release is being issued pursuant to Rule 135c under the Securities Act of 1933, as amended, and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
CONTACTS: | ||
Investors/Media: | Investors: | Media: |
Stephen Mock | Nina Goworek | Heather Zoumas Lubeski |
(845) 364-4833 | (484) 216-6657 | (484) 216-6829 |
